6Rector T S, Cohn J N. Assessment of Patient Outcome with the Minnesota Living with Heart Failure Questionnaire: Reliability and Validity during a Randomized, Double-blind, Placebo -controlled Trial of Pimobendan. Pimobendan Muhicenter Research Group [J]. Am Heart J, 1992, 124 (4): 1017-1025.
7O'Loughlin C, Murphy N F, Cordon C, et al. Quality of Life Predicts Outcome in a Heart Failure Disease Management ProgTam[J]. IntJCardiol, 2010, 139 (1): 60-67.
8Konstan V, Salem D, Pouleur H, et 81. Baseline quality of life as a predictor of mortality and hospitalization in 5.025 patients with congestive hear failure [J]. Am J Cardiol, 1996, 78 (8) : 890- 895.
9Johnos G, Carson P, Francrs GS, et at. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapri. Veterans Affaire Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT H) .V-HeFT VA 120- operative Studies Group [J]. Grenlatron, 1993, 87 (6 suppl 1): V132-V139.
